- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
PARP Inhibitors in Breast Cancer: a Short Communication ; volume:26 ; number:2 ; day:2 ; month:1 ; year:2024 ; pages:103-113 ; date:2.2024
Current oncology reports ; 26, Heft 2 (2.1.2024), 103-113, 2.2024
- Creator
-
Daly, Gordon R.
AlRawashdeh, Maen Monketh
McGrath, Jason
Dowling, Gavin P.
Cox, Luke
Naidoo, Sindhuja
Vareslija, Damir
Hill, Arnold D. K.
Young, Leonie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11912-023-01488-0
- URN
-
urn:nbn:de:101:1-2404301316474.583297901802
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Daly, Gordon R.
- AlRawashdeh, Maen Monketh
- McGrath, Jason
- Dowling, Gavin P.
- Cox, Luke
- Naidoo, Sindhuja
- Vareslija, Damir
- Hill, Arnold D. K.
- Young, Leonie
- SpringerLink (Online service)
Other Objects (12)
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
Prostate cancer and PARP inhibitors: progress and challenges
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
Prostate cancer and PARP inhibitors: progress and challenges
Advances in using PARP inhibitors to treat cancer
PARP inhibitors
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Advances and perspectives of PARP inhibitors
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
PARP inhibitors in the management of breast cancer: current data and future prospects
PARP Inhibitors in Ovarian Cancer: A Review
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
PARP inhibitors in the treatment of ovarian cancer
Prostate cancer and PARP inhibitors: progress and challenges